Vinay Mathew Thomas
Overview
Explore the profile of Vinay Mathew Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campbell P, Gebrael G, Narang A, Hage Chehade C, Mathew Thomas V, Galarza Fortuna G, et al.
Ther Adv Urol
. 2024 Nov;
16:17562872241293779.
PMID: 39524157
Background And Objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied...
2.
Narang A, Gebrael G, Jo Y, Mathew Thomas V, Li H, Galarza Fortuna G, et al.
Kidney Cancer
. 2024 Sep;
8(1):135-142.
PMID: 39263256
Background: Cabozantinib, a tyrosine kinase inhibitor (TKI), is a prevalent second-line (2 L) therapy and was approved for use after progression on TKIs. However, the 1 L treatment setting has...
3.
Galarza Fortuna G, Chigarira B, Mathew Thomas V, Sahu K, Kumar S, Tripathi N, et al.
J Kidney Cancer VHL
. 2024 Aug;
11(3):13-22.
PMID: 39100549
Thromboembolic events (TE) are a common complication in patients with metastatic renal cell carcinoma (mRCC) and are associated with poorer clinical outcomes. However, the incidence of TE and clinical and...
4.
Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2423186.
PMID: 39023888
Importance: Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). Objective: To assess trends and...
5.
Tripathi N, Gebrael G, Chigarira B, Sahu K, Balasubramanian I, Caparas C, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893262
Metastatic urinary tract cancer (mUTC) is challenging to treat in older adults due to comorbidities. We compared the clinical courses of younger and older (≥70 years) adults with mUTC receiving...
6.
Mathew Thomas V, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, et al.
JCO Precis Oncol
. 2024 May;
8:e2300574.
PMID: 38781543
Purpose: An increased BMI is linked to increased prostate adenocarcinoma incidence and mortality. Baseline tumor gene expression profiling (GEP) can provide a comprehensive picture of the biological processes related to...
7.
Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, et al.
Eur Urol Oncol
. 2024 May;
7(6):1462-1468.
PMID: 38735779
Background And Objective: It has been reported that patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) have worse prognosis and outcomes than those whose cancer relapses after prior local...
8.
Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, et al.
JAMA Netw Open
. 2024 May;
7(5):e249417.
PMID: 38696168
Importance: The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known...
9.
Coletta A, Simon L, Maslana K, Taylor S, Larson K, Hansen P, et al.
BMC Cancer
. 2024 Apr;
24(1):493.
PMID: 38637770
Background: Muscle mass is important for metastatic prostate cancer survival and quality of life (QoL). The backbone of treatment for men with metastatic castration sensitive prostate cancer (mCSPC) is androgen...
10.
Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, et al.
Cancer
. 2024 Apr;
130(15):2621-2628.
PMID: 38564301
Introduction: Rechallenge with antibodies targeting programmed cell death protein-1 or its ligand (PD-1/L1) after discontinuation or disease progression in solid tumors following a prior PD-1/L1 treatment is often practiced in...